Applied DNA Partners With Cornell University College Of Veterinary Medicine To Accelerate Development Of Veterinary Vaccine Platform Targeting Diseases That Impact High-Value Animals
Portfolio Pulse from Benzinga Newsdesk
Applied DNA Sciences Inc. has partnered with Cornell University College of Veterinary Medicine to speed up the development of a veterinary vaccine platform. The focus is on diseases that affect high-value animals. The partnership aims to develop LNP-encapsulated LineaDNA™ vaccines to eliminate the use of plasmid DNA and reduce dependence on extreme cold chains of today's mRNA vaccines.
September 14, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Applied DNA Sciences' partnership with Cornell University could potentially boost its stock as it indicates progress in the development of a new veterinary vaccine platform.
The partnership with Cornell University is a positive development for Applied DNA Sciences as it could lead to the creation of a new veterinary vaccine platform. This could potentially increase the company's revenues and profitability in the future, which would likely have a positive impact on its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100